APRE - Aprea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.32
+1.27 (+4.88%)
At close: 4:00PM EST

27.32 0.00 (0.00%)
After hours: 5:01PM EST

Stock chart is not supported by your current browser
Previous Close26.05
Open26.31
Bid27.08 x 800
Ask27.48 x 800
Day's Range26.31 - 30.94
52 Week Range15.10 - 32.04
Volume283,906
Avg. Volume125,200
Market Cap573M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-26.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.67
  • GlobeNewswire

    Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

    Aprea Therapeutics, Inc. (APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented results at the 2019 ASH Annual Meeting from its U.S. Phase Ib/II clinical trial in MDS and AML. The trial is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS and AML.

  • GlobeNewswire

    Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

    BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented preliminary results at the 2019 ASH Annual Meeting from its French Phase Ib/II clinical trial in MDS and AML. The trial is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of patients with TP53 mutated MDS and AML. The clinical trial is sponsored by the Groupe Francophone des Myélodysplasies.

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
    Zacks

    Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?

    Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

  • GlobeNewswire

    Aprea Therapeutics Reports Third Quarter 2019 Financial Results

    BOSTON, Nov. 14, 2019 -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that.

  • RBC: 3 Stock Picks Set to Soar 30%+
    TipRanks

    RBC: 3 Stock Picks Set to Soar 30%+

    Global investment bank, RBC Capital, is one of the finance world’s heavy hitters. It is the 5th largest in North America, and with 70 offices in 15 countries around the world, it has a stellar reputation. This international reputation and the financial clout that comes with it, naturally attracts top talent, and top talent can bring home the bacon, so to speak. It is no wonder then that RBC leads TipRanks’ list of Top Performing Research Firms.With this in mind, we decided to take a look at some of the recent stock recommendations from RBC analysts, specifically ones with potential for 30%+ gains ahead.Agile Therapeutics (AGRX)Agile Therapeutics shares took a nosedive in late October after briefing documents released by the FDA expressed concern regarding the “effectiveness in proportion to its safety,” of Twirla, the company’s contraceptive patch, ahead of an AdCom review. As it happens, the review panel voted in favor of approval, which coincidentally, sent the stock skyrocketing.Following the AdCom’s positive outcome, RBC surveyed physicians to better understand the experts’ view on Twirla. The results echoed those of the AdCom, and with the PDUFA set for November 16, the impression is that Twirla will most likely be granted approval by the FDA.RBC analyst Randall Stanicky noted, “We could see approval this week or alternatively a potential ~3month delay as FDA works through labeling; either way we think shares at these levels show attractive near-term upside… Our survey of 40 OB/GYNs was surprisingly bullish on desire for Twirla as a contraceptive option; this increases our conviction that there is a place for it in the market.”As a result, Stanicky reiterates a Buy rating on AGRX along with a $5.00 price target, which implies a whopping upside of 130% from current levels. (To watch Stanicky’s track record, click here)How does Stanicky's bullish bet weigh in against the Street? It appears the analyst is not the only one enthusiastic on this healthcare stock, with TipRanks analytics demonstrating AGRX as a Strong Buy. This breaks down into 5 "buy" ratings in the last three months. With a return potential of over 100%, the stock’s consensus target price stands at $4.50. (See Agile stock analysis on TipRanks)Rapid7 (RPD)Cyber-security firm, Rapid7, provides data and analytics software to help organizations keep their networks safe from malicious cyber threats. Basically, it does what it says on the tin and reduces risk across a connected environment.Last week, Rapid7 delivered stronger quarterly results than expected, with annualized recurring revenue (ARR) growing by 43% on top of 17% customer growth. Overall, the company posted earnings of one cent per share on revenue of $83.16 million, beating the loss of 3 cents and revenue of $80.12 million analysts expected. Therefore, the company has now raised 2019 revenue guidance from $319 million to $323.5 million.Citing Rapid7 as a favorite SMID-cap, RBC’s 5-star analyst Matthew Hedberg believes that although estimates have gone higher, they still look beatable. Hedberg noted, “ARR growth is the key metric, as management expects it to remain at or above 30% through 2020. While the stock has performed well, we continue to believe it represents an attractive investment… In addition to new customer additions, we believe 2020 should see the cross-sale of additional products like InsightIDR and InsightAppSec and longer-term InsightConnect. This value generation was shown in ARR per customer, which grew 22% y/y… Our estimates move higher, but we still believe upside remains through 2020…”This has led Hedberg to keep his Buy rating along with a price target of $81.00. With RPD currently trading at $51.08, this provides upside of about 60%. (To watch Hedberg’s track record, click here).Looking at the consensus breakdown, the cyber-security firm has amassed 8 Buys and 1 Hold in the last three months, making Rapid7 a Strong Buy. The average stock-price forecast is $65.50. Not quite as bullish as Hedberg, this target still provides upside of 28% from its current price. (See Rapid7 price targets and analyst ratings on TipRanks)Aprea Therapeutics (APRE)Aprea Therapeutics is a Boston, Massachusetts-based biopharma focused on developing and bringing to market novel cancer therapeutics that reactivate mutant tumor suppressor protein p53. Aprea’s main drug candidate is APR-246, a small molecule in clinical development designed to treat various forms of cancer with TP53 mutations. These are found in half of all cancers. Through its unique design, APR-246 is able to restore immune defenses and promote apoptosis of cancer cells.The company will present updated data from its phase II trial in December, and it believes APR-246 will be a first-in-class therapy if approved by regulators.RBC’s Gregory Renza agrees, saying, “We believe APRE’s small molecule p53 reactivator pipeline in oncology, led by APR-246, has ample potential given the data to date and catalyst setup expected over the year. We see APRE emerging as a competitive player in the oncology space, especially in severe TP53 populations where unmet need is high, and believe in its potential for long-term share appreciation as the programs continue to de-risk… If approved, we see prospects of $800M WW peak sales in MDS at a ~35% POS, driving 2/3 of our valuation.”Renza initiated coverage with a bullish call and set a price target of $33.00, indicating upside of over 32%. (To watch Renza’s track record, click here)It’s a tad quiet when it comes to analyst coverage, with only two other analysts currently providing ratings for APRE, both recommending a Hold. With an average price target of $26.33 providing a modest 5% upside from its current price, the biopharma newbie ranks as a Moderate Buy. (See Aprea price targets and analyst ratings on TipRanks)

  • GlobeNewswire

    Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting

    BOSTON, Nov. 06, 2019 -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that.

  • Insiders Roundup: Facebook, American Defense Systems
    GuruFocus.com

    Insiders Roundup: Facebook, American Defense Systems

    Largest insider trades of the week Continue reading...

  • Benzinga

    Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO

    Aprea Therapeutics Inc (NASDAQ: APRE ) shares cooled a bit Tuesday after getting off to a hot start on the market following an Oct. 3 IPO . The oncology biotech company, which is conducting Phase III testing, ...

  • GlobeNewswire

    Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    BOSTON, Oct. 07, 2019 -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that.

  • MarketWatch

    Aprea Therapeutics' stock opens 3.1% above IPO price, then rises further

    Aprea Therapeutics Inc. got off to a positive start as a public company Thursday, as the first trade of the cancer treatment developer's stock was 3.1% above its $15 initial public offering price. The first trade was $15.46 at 10:19 a.m. Eastern, and the stock has gained since to be up 12% in recent trading. The IPO priced late Wednesday in the middle of the expected range of $14 to $16. The biopharmaceutical company sold 5 million shares in the IPO to raise $75 million, and was valued at $288.15 million. The joint book-running managers were J.P. Morgan, Morgan Stanley and RBC Capital Markets. The company recorded a net loss of $8.7 million on no revenue during the first six months of 2019, compared with a loss of $7.7 million on no revenue in the same period last year. Aprea went public at a time the Renaissance IPO ETF has lost 13.3% over the past three months, the iShares Nasdaq Biotechnology ETF has declined 11.6% and the S&P 500 has slipped 3.3%.

  • GlobeNewswire

    Aprea Therapeutics Announces Pricing of Initial Public Offering

    BOSTON, Oct. 02, 2019 -- Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor.

  • Benzinga

    IPO Outlook For The Week: Banks And Biotechs

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. ADC Therapeutics SA (NYSE: ADCT ) will issue nearly 8.2 million shares ...

  • MarketWatch

    Aprea Therapeutics to offer 5 million shares in its IPO, priced at $14 to $16 each

    Aprea Therapeutics set terms for its planned initial public offering on Monday, saying in a regulatory filing that it plans to issue 5 million shares priced at $14 to $16 each. The company has applied to list on Nasdaq under the ticker symbol "APRE." JPMorgan, Morgan Stanley and RBC are underwriters on the deal. Proceeds will be used to fund clinical trials, R&D and for working capital. "We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein," the company said in its prospectus.